Adjuvant low-dose rituximab and plasma exchange for acquired TTP
摘要
TO THE EDITOR: The introduction of plasmapheresis with plasma exchange has increased survival in patients with thrombotic thrombocytopenic purpura (TTP) from <10% to 80%.[1][1] More than 30% of patients with TTP have at least 1 relapse within 2 years.[2][2] Treatment with rituximab normalizes
引用本文（GB/T 7714）
Jeffrey I. Zwicker, Joshua Muia, Leili Dolatshahi, 等. Adjuvant low-dose rituximab and plasma exchange for acquired TTP[J]. Blood, 2019.
引文网络
本站仅收录题录与摘要供学习参考，全文版权归属出版方；如有侵权请联系我们删除。